QualityStocksNewsBreaks – Artelo Biosciences Inc. (NASDAQ: ARTL) Appoints Senior Pharmaceutical Exec as New SVP, Chief Scientific Officer
Artelo Biosciences (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as senior vice president and chief scientific officer. Dr. Yates is an experienced senior pharmaceutical executive, having most recently served at AstraZeneca in significant roles across a number of functional areas including development and commercial strategy, medical affairs and business development. Notably, Dr. Yates has been extensively involved in the life-cycle management of key multi-billion-dollar products including CRESTOR(R), FORXIGA(R) and KEYTRUDA(R). “We are extremely pleased to announce the…
